Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.08.2010 | Preclinical study

Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population

verfasst von: A-Yong Cao, Ke-Da Yu, Wen-Jin Yin, Wei Jin, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Certain rare germline mutations in the PALB2 gene have been confirmed to increase susceptibility to breast cancer in diverse populations, but it has not been very clear that whether some common polymorphic variants in PALB2 also increase breast cancer risk. We conducted a case–control study to validate the association of common variations in the PALB2 gene and breast cancer in eastern Chinese population. A total of six common single nucleotide polymorphisms (rs8053188, rs16940342, rs249954, rs447529, rs249935, and rs3096145), which tagged the known common variants (minor allele frequency >0.1) of PALB2, were genotyped among 660 cases and 756 cancer-free controls by SNPstream assay. Except rs3096145, other five SNPs passed the quality assessment criteria with genotyping call rate >95%. Genotype and allele frequencies were statistically different between cases and controls for PALB2 rs447529 and rs249935. PALB2 rs249935 G allele was related to a 1.21-fold (95% confidence interval = 1.02–1.43) increase in risk for each ‘A’ allele carried (P = 0.029). Based on the dominant inheritance model tests, we found that compared with rs447529 CC homozygotes, the variant homozygote GG and heterozygote GC carriers had a 0.43-fold decreased risk of breast cancer (95% confidence interval = 0.24–0.78, P = 0.005). Combined with the results of the former study, our findings further verified that some common PALB2 polymorphisms may contribute to the etiology of breast cancer in Chinese women, so other large studies are warranted to confirm these observations in different ethnic populations.
Literatur
1.
2.
Zurück zum Zitat Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729CrossRefPubMed Xia B, Sheng Q, Nakanishi K et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729CrossRefPubMed
3.
Zurück zum Zitat Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed
4.
Zurück zum Zitat Cao AY, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114(3):457–462CrossRefPubMed Cao AY, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114(3):457–462CrossRefPubMed
5.
Zurück zum Zitat Zheng SL, Sun J, Wiklund F et al (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358(9):910–919CrossRefPubMed Zheng SL, Sun J, Wiklund F et al (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358(9):910–919CrossRefPubMed
6.
Zurück zum Zitat Chen P, Liang J, Wang Z et al (2008) Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 14(18):5931–5937CrossRefPubMed Chen P, Liang J, Wang Z et al (2008) Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 14(18):5931–5937CrossRefPubMed
7.
Zurück zum Zitat Pattaro C, Ruczinski I, Fallin DM et al (2008) Haplotype block partitioning as a tool for dimensionality reduction in SNP association studies. BMC Genomics 9:405CrossRefPubMed Pattaro C, Ruczinski I, Fallin DM et al (2008) Haplotype block partitioning as a tool for dimensionality reduction in SNP association studies. BMC Genomics 9:405CrossRefPubMed
8.
Zurück zum Zitat de Bakker PI, Yelensky R, Pe’er I et al (2005) Efficiency and power in genetic association studies. Nat Genet 37(11):1217–1223CrossRefPubMed de Bakker PI, Yelensky R, Pe’er I et al (2005) Efficiency and power in genetic association studies. Nat Genet 37(11):1217–1223CrossRefPubMed
9.
Zurück zum Zitat Kong Q, Ma X, Li F et al (2007) COL6A1 polymorphisms associated with ossification of the ligamentum flavum and ossification of the posterior longitudinal ligament. Spine 32(25):2834–2838CrossRefPubMed Kong Q, Ma X, Li F et al (2007) COL6A1 polymorphisms associated with ossification of the ligamentum flavum and ossification of the posterior longitudinal ligament. Spine 32(25):2834–2838CrossRefPubMed
10.
11.
Zurück zum Zitat Marini F, Nardo T, Giannattasio M et al (2006) DNA nucleotide excision repair-dependent signaling to checkpoint activation. Proc Natl Acad Sci USA 103(46):17325–17330CrossRefPubMed Marini F, Nardo T, Giannattasio M et al (2006) DNA nucleotide excision repair-dependent signaling to checkpoint activation. Proc Natl Acad Sci USA 103(46):17325–17330CrossRefPubMed
14.
Zurück zum Zitat Tao W, Wang C, Han R, Jiang H (2009) HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 114(2):371–376CrossRefPubMed Tao W, Wang C, Han R, Jiang H (2009) HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 114(2):371–376CrossRefPubMed
Metadaten
Titel
Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population
verfasst von
A-Yong Cao
Ke-Da Yu
Wen-Jin Yin
Wei Jin
Gen-Hong Di
Zhen-Zhou Shen
Zhi-Ming Shao
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0637-1

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.